Search results
This clinical handbook has been created to serve as a compendium of the evidence-based rationale and clinical consensus for Hyperbilirubinemia in Term and Late-Pre-Term Infants (≥ 35 weeks). This document has been prepared for informational purposes only.
American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Clinical Practice Guideline for the Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation.
Hyperbilirubinemia Care Guideline for Emergency Department Management. Inclusion Criteria: Previously healthy, age ≤ 14 days, born at ≥ 35 weeks gestation; Appears jaundice. Exclusion Criteria: Suspected sepsis or ill-appearing; Signs of acute bilirubin encephalopathy; Elevation of the direct bilirubin.
CLINICAL PATHWAY MANUAL for. Midwifery Hyperbilirubinemia Screening and Management of Phototherapy. PURPOSE. herapy management for hyperbilirubinemia in infants in their care. It is meant to be used in conjunction with the Association of Ontario Midwives’ (AOM) clinical practice guideline (CPG) No. 18: Manageme.
Hyperbilirubinemia in the newborn, also referred to as neonatal jaundice, is a result of the diminished ability to conjugate and excrete an excess of bilirubin in the blood of the neonate (Mosby, 2009). Hyperbilirubinemia is a common condition affecting approximately 60% of term and 80% of pre-term
infants being evaluated and treated for neonatal hyperbilirubinemia for patients greater than or equal to 35 weeks gestational age. It addresses the following clinical questions or problems:
People also ask
What is the Clinical handbook for hyperbilirubinemia?
What is the latest guidance on hyperbilirubinemia management?
When will a clinical guideline for hyperbilirubinemia expire?
What is AAP clinical guidance for hyperbilirubinemia in newborns?
Hyperbilirubinemia Overview. Severe hyperbilirubinemia can cause kernicterus, a type of brain damage that leads to movement problems (cerebral palsy) and hearing loss. Informed guidance on hyperbilirubinemia management, including preventive treatment thresholds, is critical to safely minimize neurodevelopmental risk.
